Antitumor activity of lymphocytes upon the development of the resistance to doxorubicine in MCA-rhabdomyosarcoma-bearing mice

Experimental Oncology

Volumn 24, Issue 4, 2002, Pages 292-294

  Berezhnaya, N M ^a   Kovalchuk, E V ^a   Spivak, S I ^a   Vinnichuk, U D ^a   Kotova, S A ^a   Belova, O B ^a   Shlyakhovenko, V A ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Antitumor activity; Chemoresistance; Doxorubicine; Lymphocytes

Indexed keywords

DOXORUBICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG SENSITIVITY; LYMPHOCYTE; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; RHABDOMYOSARCOMA;

EID: 0036971596     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Foreman NK, Rill DR, Coustan-Smith E, Douglass EC, Brenner MK. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual eradication. Br J Cancer 1993; 67: 933-8.
2. Gautam SC, Chikkala NF, Lewis I, Grabowski DR, Finke JH, Ganapathi R. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma. Anticancer Res 1992; 12: 921-5.
3. Mazzoni A, Trave F, Fabbri M, Leto G, Ghidoni R. Membrane gangliosides and immuno-mediated cytolysis in drug sensitive and treatment induced multidrug resistant human ovarian cancer cells. Anticancer Res 1991; 11: 2181-5.
4. Mooney EF, Dye GF, Guillou PG, Monson GR. Multidrug-resistant colonic cancer cell line LoVoDx is efficiently killed by lymphokine-activated killer cells from patients with carcinoma of the colon. Br J Surg 1993; 80: 1259-61.
5. Ramoni C, Dupuis ML, Cenciarelli C, Ciccolini F, Cianfriglia M. Susceptibility of multidrug-resistant human T-lymphoblastoid CEM cell line to cell-mediated cytolysis. Ann Ist Super Sanita 1990; 26: 433-9.
6. Savas B, Cole SP, Tsuruo T, Pross HF. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma. J Clin Immunol 1996; 16: 348-57.
7. Rivoltini L, Colombo MP, Supino R, Ballinari D, Tsuruo T, Parmiani G. Modulation of multidrug resistance by verapamil or mdr-1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killer in mdr-resistant human carcinoma (LoVo) line. Int J Cancer 1990; 46: 727-32.
8. Grunberg E, Eckert K, Mauer HR. Docetaxel treatment of HT-29 colon carcinoma cells reinforced the adhesion and immunocytotoxicity of peripheral blood lymphocytes in vitro. Int J Oncol 1998; 12: 957-63.
9. Berezhnaya NM, Kovalchuk EV, Denisevich TV, Osipova EV, Konovalenko VF, Tolstopyatov BA, Trembach AM, Protsik VS, Vorobyeva LI, Pinchuk VG, Yakshibaeva YuP. Comparison of the influence of immunomodulators of different origin on the growth of the explants and isolated tumor cells of men and animals. Exp Oncol 1996; 18: 244-50 (In Russian).
10. Giavazzi R, Campbell EB, Jessup JM, Cleari K, Fidler IJ. Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice. Cancer Res 1986; 46: 1928-33.
11. Stukov AN, Ivanova MA, Nikitin AK, Sorokin GM, Kon'kov SA. Index of tumor growth as integral criterium of the efficacy of antitumor therapy in vivo. Vopr Oncol 2001; 47: 616-8 (In Russian).
12. Elia MC, DeLuca JG, Brodley MO. Significance and measurement of DNA double strong breaks in mammalian cells. Pharm Therap 1991; 51: 291-327.
13. Berczi I, Bertok L, Chow DA. Natural immunity and neuroimmune host defense. Ann N Y Acad Sci 2000; 917: 248-57.
14. Berezhnaya NM, Chekhun VF. The system of interleukins and cancer. Kyiv: DIA 2000; 224 p. (In Russian).
15. O'Brien PM, Tsirimonaki E, Coomber DW, Millan DW, Davis JA, Campo MS. Immunoglobulin genes expressed by B-lymphocytes infiltrating cervical carcinomas show evidence of antigen-drived selection. Cancer Immunol Immunother 2001; 54: 2367-72.
16. Rossig C, Nuchtern JG, Brenner MK. Selection of human antitumor single-chain Fv antibodies from the B-cell repertoire of patients immunized against autologous neuroblastoma. Med Pediatr Oncol 2000; 35: 692-5.
17. Ito O, Harada M, Takenoyama M, Sumichika H, Matsuzaki G, Nomoto K. An increase of B-cells in the tumor-bearing state has the potential to induse anti-tumor immunity. Immunobiol 1996; 195: 1-15.
18. Browning J, Dougas I, Ngamek A, Bourdon PR, Ehrenfels BN. Characterization of surface lymphotoxin forms. Use of specific monoclonal antibobies and soluble receptors. J Immunol 1995; 154: 33-9.
19. Wazzocha K, Bienvenu J, Coiffer B, Salles G. Mechanisms of action of tumor necrosis factor and lymphotoxin ligand-receptor system. Eur Cytokine Netw 1994; 5: 83-96.
20. Weaver DJ, Voss EW. A novel cellular interaction involving antigen-pulsed macrophage and antigen-specific B-lymphocytes. Mol Immunol 2000; 37: 311-20.
21. Ismaili J. In vivo and in vitro assessement of B-B-cell interaction inhibition of proliferation and antibody of CRIA B-cells mediated by the surface immunoglobulins of anti CRIA B-cells. Eur J Immunol 1998; 28: 1358-67.